Agilent Technologies (NYSE:A) Price Target Raised to $180.00 at Bank of America

Key Points

• Bank of America raised Agilent Technologies’ price target to $180 from $155 and maintained a “buy” rating, implying approximately 14.5% upside from the reported share price.
• Agilent exceeded quarterly expectations with $1.62 adjusted EPS and $1.88 billion in revenue, while revenue increased 8.1% year over year. The company also issued fiscal 2026 EPS guidance of $6.18–$6.21.
• Analyst sentiment remains broadly positive: Agilent has a “Moderate Buy” consensus rating and an average price target of $170.33, with several firms recently raising their targets, including JPMorgan at $190.

Agilent Technologies (NYSE:A - Get Free Report) had its price objective upped by analysts at Bank of America from $155.00 to $180.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the medical research company's stock. Bank of America's target price points to a potential upside of 14.49% from the company's current price.

A number of other research firms also recently weighed in on A. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Sunday, August 2nd. Morgan Stanley boosted their price objective on Agilent Technologies from $160.00 to $175.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. upped their target price on shares of Agilent Technologies from $180.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday. TD Cowen increased their price objective on shares of Agilent Technologies from $155.00 to $180.00 and gave the company a "buy" rating in a report on Thursday. Finally, Piper Sandler initiated coverage on shares of Agilent Technologies in a research note on Thursday, June 11th. They issued a "neutral" rating and a $150.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $170.33.

Agilent Technologies Price Performance

Shares of NYSE A traded up $2.13 during trading on Thursday, reaching $157.22. The company had a trading volume of 1,992,931 shares, compared to its average volume of 2,232,849. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $163.75. The business's 50 day moving average price is $139.16 and its 200-day moving average price is $126.65. The stock has a market cap of $44.40 billion, a PE ratio of 31.56, a PEG ratio of 2.73 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.49 by $0.13. The business had revenue of $1.88 billion for the quarter, compared to analysts' expectations of $1.84 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies's revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Analysts expect that Agilent Technologies will post 6.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of A. Brighton Jones LLC increased its stake in Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after purchasing an additional 270 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company's stock worth $602,000 after purchasing an additional 769 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Agilent Technologies by 54.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company's stock valued at $70,000 after buying an additional 212 shares during the period. Acadian Asset Management LLC increased its position in shares of Agilent Technologies by 16.5% in the 1st quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock valued at $625,000 after buying an additional 758 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in Agilent Technologies during the 2nd quarter worth $273,000. Institutional investors own 87.41% of the company's stock.

Key Stories Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source